Psylos1

Psylos1 sells functional mushroom supplements and nootropic blends in capsule, powder, and liquid-extract form. SKUs span micro-dosed psilocybin analog stacks, lion’s-mane/cordyceps blends, and sleep-terpene complexes; most SKUs sit in a mid-range tier of USD 35–65 per 30-serving unit. All commerce is DTC through psylos1.com; no retail or marketplace listings are operated. The brand positions itself as a “quantified cognition” company: every batch is 3rd-party lab-tested for beta-glucans, terpenes, and alkaloid analogs, with QR-linked certificates posted publicly. Its flagship “Psylos1 Micro” stack combines 0.1 g legal psilocybin-mimetic extract with niacin and lion’s mane, a formulation popularized in early bio-hacker forums and now the site’s top-selling SKU. Core buyers are 25-40-year-old tech workers, endurance athletes, and creative freelancers who track productivity with wearables and value neuroplasticity over recreational highs. The brand voice is data-first and harm-reductionist, appealing to consumers who want protocol-based dosing without dark-web risk or clinical gatekeeping. Psylos1 competes with two groups: mainstream adaptogen brands that stay strictly non-psychedelic and gray-market micro-dose vendors that offer raw mushrooms without testing. It differentiates by delivering federally legal, standardized analogs in GMP-certified capsules, shipping with discreet, FDA-compliant labels, and publishing full-panel lab data—bridging safety gaps both sides leave open.